A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy

被引：0

作者：

Nannis, Gabriel N. ^{[1
]}

Griffiths, Elizabeth A. ^{[2
]}

Savona, Michael R. ^{[3
]}

Odenike, Olatoyosi ^{[4
]}

Roboz, Gail J. ^{[5
]}

O'Connell, Casey L. ^{[6
]}

Dillingham, Jacqueline ^{[7
]}

Wason, Prieya ^{[7
]}

Zhu, Lixia ^{[7
]}

Chan, Danna ^{[7
]}

Keer, Harold N. ^{[7
]}

Oganesian, Aram ^{[7
]}

Dao, Kim-Hien ^{[7
]}

DiNardo, Courtney D. ^{[8
]}

机构：

[1] Stanford Univ, Div Hematol, Dept Med, Sch Med, Stanford, CA USA

[2] Roswell Pk Comprehens Canc Ctr, New York, NY USA

[3] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN USA

[4] Univ Chicago, Chicago, IL USA

[5] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[6] Univ Southern Calif, USC Keck Sch Med, Los Angeles, CA USA

[7] Astex Pharmaceut Inc, Pleasanton, CA USA

[8] Univ Texas MD, Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146264

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1245

引用

页数：5

共 50 条

[1] A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia
Bazinet, Alexandre
Garcia-Manero, Guillermo
Short, Nicholas J.
Valero, Yesid Alvarado
Abuasab, Tareq
Islam, Md Rabiul
Montalbano, Kathryn
Issa, Ghayas C.
Maiti, Abhishek
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven M.
Jabbour, Elias
Montalban-Bravo, Guillermo
Pierce, Sherry
DiNardo, Courtney D.
Kadia, Tapan M.
Daver, Naval
Konopleva, Marina Y.
Kantarjian, Hagop M.
Ravandi, Farhad
BLOOD, 2023, 142
[2] Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy
Abuasab, Tareq
Garcia-Manero, Guillermo
Short, Nicholas
Alvarado, Yesid
Issa, Ghayas C.
Islam, Rubiul
Maiti, Abhishek
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven M.
Jabbour, Elias
Pemmaraju, Naveen
Montalban-Bravo, Guillermo
Pierce, Sherry A.
DiNardo, Courtney D.
Kadia, Tapan M.
Daver, Naval
Konopleva, Marina
Kantarjian, Hagop
Ravandi, Farhad
BLOOD, 2022, 140 : 3324 - 3326
[3] Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.
Ravandi, Farhad
Abuasab, Tareq
Valero, Yesid Alvarado
Issa, Ghayas C.
Islam, Rabiul
Short, Nicholas James
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven Mitchell
Jabbour, Elias
Pemmaraju, Naveen
Bravo, Guillermo Montalban
Pierce, Sherry
Dinardo, Courtney Denton
Kadia, Tapan M.
Daver, Naval Guastad
Konopleva, Marina
Garcia-Manero, Guillermo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy
Abuasab, Tareq
Alvarado, Yesid
Issa, Ghayas
Islam, Rabiul
James, Nicholas
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven
Jabbour, Elias
Pemmaraju, Naveen
Bravo, Guillermo Montalban
Pierce, Sherry
DiNardo, Courtney
Kadia, Tapan
Daver, Naval
Konopleva, Marina
Garcia-Manero, Guillermo
Ravandi, Farhad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S237 - S237
[5] ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
Garcia-Manero, Guillermo
Bachiashvili, Kimo
Amin, Harshad
Traer, Elie
Pollyea, Daniel A.
Sallman, David A.
Al-Kali, Aref
Cripe, Larry D.
Berdeja, Jesus G.
Griffiths, Elizabeth A.
Mohan, Sanjay R.
Sano, Yuri
Oganesian, Aram
Keer, Harold N.
Yacoub, Abdulraheem
BLOOD, 2022, 140 : 1112 - 1114
[6] A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naive High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Venugopal, Sangeetha
Kantarjian, Hagop
Maiti, Abhishek
Short, Nicholas J.
Montalban-Bravo, Guillermo
Alvarado, Yesid
Chien, Kelly S.
Kanagal-Shamanna, Rashmi
Pemmaraju, Naveen
Davel, Naval
Kadia, Tapan M.
Borthakur, Gautam
Jabbour, Elias J.
Garcia-Manero, Guillermo
BLOOD, 2021, 138
[7] A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naive High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Venugopal, Sangeetha
Kantarjian, Hagop
Maiti, Abhishek
Short, Nicholas J.
Montalban-Bravo, Guillermo
Alvarado, Yesid
Chien, Kelly
Kanagal-Shamanna, Rashma
Pemmaraju, Naveen
Daver, Naval
Kadia, Tapan
Borthakur, Gautam
Jabbour, Elias
Garcia-Manero, Guillermo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S321 - S321
[8] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy
Ong, Faustine
Short, Nicholas
Daver, Naval
Kadia, Tapan M.
DiNardo, Courtney D.
Yilmaz, Musa
Alvarado, Yesid
Vaughan, Kenneth
Pierce, Sherry A.
Kantarjian, Hagop
Garcia-Manero, Guillermo
Ravandi, Farhad
BLOOD, 2022, 140 : 9029 - 9031
[9] PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS
Garcia-Manero, G.
Bachiashvili, K.
Amin, H.
Traer, E.
Pollyea, D.
Sallman, D.
Al-Kali, A.
Cripe, L.
Berdeja, J.
Griffiths, E.
Mohan, S.
Vachhani, P.
Sano, Y.
Oganesian, A.
Keer, H.
Yacoub, A.
LEUKEMIA RESEARCH, 2023, 128
[10] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update
Atluri, Himachandana
Mullin, Jillian
Takahashi, Koichi
Loghavi, Sanam
Maiti, Abhishek
Sasaki, Koji
Daver, Naval
Valero, Yesid Alvarado
Pemmaraju, Naveen
Borthakur, Gautam
Hammond, Danielle E.
Chien, Kelly S.
Ferrajoli, Alessandra
Short, Nicholas J.
Abbas, Hussein A.
Jabbour, Elias
Andreeff, Michael
Ravandi, Farhad
Tidwell, Rebecca S. S.
Wang, Xuemei
Konopleva, Marina Y.
Garcia-Manero, Guillermo
Kantarjian, Hagop M.
DiNardo, Courtney D.
BLOOD, 2023, 142

← 1 2 3 4 5 →